Human Milk Oligosaccharides are a collection of carbohydrate structures and the third most abundant solid component of human milk after lipids and lactose. Clinical data in infants, indicate that HMOs may help to develop the desired microbiota by serving as a food source for the good bacteria in the intestine. Naturally occurring in breast milk, HMOs have evolved over thousands of years, with HMO studies (clinical and preclinical) now suggesting that specific HMO’s at the correct level of supplementation can provide us with unique health benefits. In particular, they may help support immunity and gut health, with a potential role in cognitive development, which may open future innovation opportunities.
Next-generation HMOs are part of our exciting innovation roadmap, with four new HMOs becoming available this year for innovation trials to further catalyze the already fast-growing HMO market.
Making more variants available
There are around 200 different types of human milk oligosaccharides. Our research and development team are developing a pipeline that represents more than 75% of all HMOs.
In our research and development team, consisting of more than 30 employees, we utilize our unique combination of biotechnology and bioengineering excellence with carbohydrate chemistry expertise to develop safe, rapid and cost-effective production processes of HMOs. Our strong analytical teams support the R&D program with its in-process control and final product method development expertise.
Extensive experience in Analytical Standards
Our team has developed analytical standards for HMOs for more than 10 years. We have gained extensive experience in production of HMOs with chemical and enzymatical synthesis and fermentation technology as part of our development of commercial HMOs. The analytical standards have had key importance for our ability to quality test and control our own products.
Clinical Research and Science
To prove the impact on human health and document the mechanisms of Human Milk Oligosaccharides (HMOs), we lead a rich program of preclinical and clinical studies. Independently, and along with a substantial network of more than 40 research and strategic partners across the world.
Furthermore, we are specifically investigating the effect of our HMOs on obese children and on patients suffering from irritable bowel syndrome (IBS) in blinded and placebo-controlled clinical studies.